Cholestasis Market - Forecast(2024 - 2030)

Cholestasis Market size is valued at $6.22M by 2019, and is anticipated to grow at a CAGR of 4.9% during the forecast period 2020-2025. The Cholestasis Market growth rate is attributed to the changing lifestyle that has altered dietary pattern and results of use of certain medications that include anabolic steroids, tolbutamide, prochlorperazine, estradio, terbinafine, imipramine, chlorpromazine, birth control pills and cimetidine. Cholestasis is defined as a decrease in bile flow due to impaired secretion by hepatocytes or to obstruction of bile flow through intra-or extra hepatic bile ducts. Therefore, the clinical definition of cholestasis is any condition in which substances normally excreted into bile are retained. The serum concentrations of conjugated bilirubin and bile salts are the most commonly measured. From improvement’s made to enhance the rise in number of product innovations to financial support to the researchers for developing novel intervention is anticipated to propel the Cholestasis Market during the forecast period 2020-2025. 

The report: “Cholestasis Market Forecast (2020-2025)”,by IndustryARC, covers an in-depth analysis of the following segments of the Cholestasis Market:

By Cholestasis Type: Intrahepatic Cholestasis, Extrahepatic Cholestasis and Others.

By Diagnosis Type: Blood Tests, Imaging Tests, Biopsy and Others.

By Treatment Type: Medications and Surgery.

By Age Group: Adult, Adolescent and Pediatric and Geriatric.

By Geography: North America, Europe, Asia-Pacific and RoW.

On the basis of Cholestasis type, Intrahepatic Cholestasis segment held the major share of the market in terms of revenue and is estimated to grow with a CAGR of 3.8% during forecast period. The reason may be attributed to the most of the causes of intrahepatic cholestasis are because of both inherited and acquired liver diseases. Another major intrahepatic cholestasis type is Intrahepatic Cholestasis of Pregnancy, where the cells are unable to transport the bile out of the cells normally, which leads to bile acids building up in the blood. Elevated bile acids in the blood are associated with increased risk to the unborn baby. It is important to note that Intrahepatic Cholestasis of Pregnancy is not a single disorder, but a heterogeneous group of many different disorders which all lead to elevated bile acids. This means that the disorder presents very differently in different affected women which is anticipated to further expand the consumption rate over the projection period of 2020-2025.

On the basis of age group, pediatric and adolescent age group is more susceptible to cholestasis owing to the immaturity of the liver. Amongst the various types cholestasis inherited causes are popular such as the zinc storage disorder. This causes a marked cholestasis jaundice and liver failure found to recur after liver transplantation. The exact cause for this storage disorder remains unknown. Cholestasis in pediatric and adolescent age group is believed to rise effectively as children with cystic fibrosis caused by mutation of theCFTR gene (the gene product is located on all epithelial cells; thus biliary epithelial cells are involved)are now very common inherited disease, are prominent in individuals surviving into adulthood and is anticipated to further propel the market growth over the projection period of 2020-2025. 

North America dominated the Cholestasis Market with a share of36% in 2019. The application of Cholestasis has grown rapidly over the last few year sowing to the increased risk of intrahepatic cholestasis of pregnancy (ICP), relative to women of other ethnicities which continues to expand its market.Incidence of ICP differs between populations, and in some, has changed over time, suggesting both genetic and environmental contributions to etiology. Approximately 1% of pregnancies in the United States are affected by this condition, affecting nearly 2 out of 140 pregnant women. ICP has no clear etiology, and it is believed to be a multifactorial disorder with environmental, hormonal, and genetic contributions. High initial capital investment on infrastructure, increasing production capacities of UHT treatment plants and requirement for very high-quality milk for UHT treatment are to cater the Cholestasis Market in the forecast period of 2020-2025.

With the growing population ensures increased occurrences of the disease amongst children along with the number of pregnancies is likely to increase in the near future, so is the prevalence of cholestasis. Moreover, cholestasis can be hereditary in nature and there is a significant presence of chronic cholestasis in children owing to the nature of the disease which is set to act as a key driver of the market during the forecast period 2020-2025. 

The major challenge for the market is the high initial capital investment on infrastructure and the requirement for cholestasis treatment and compliance of these Cholestasis in a vast and heterogeneous market. The stringent rules and regulations regarding the development of efficient diagnostic tests with early detection of the disease is the major problem for some of the regions in Asia-Pacific. 

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Cholestasis Market. In 2019,Cholestasis Market is estimated to be fragmented in nature. Cholestasis Market top 10 companies are Eli Lily and Company, Palmetto Health, Abbott Laboratories, Teva Pharmaceutical Industries Ltd, Zydus Cadila, ALLERGAN, Endo Pharmaceuticals Inc, ANI Pharmaceuticals Inc, Glenmark Pharmaceuticals Ltd, Amneal Pharmaceuticals LLC, and others.